First-line immunotherapy in PD-L1-high non-small cell lung cancer: indirect treatment comparison of pembrolizumab and atezolizumab

被引：0
|
作者：
Griesinger, F. [1 ]
Sibbe, M. S. [2 ]
Hieke-Schulz, S. [2 ]
Buhck, H. [2 ]
Reinmuth, N. [3 ]
Rittmeyer, A. [4 ]
机构：
[1] Pius Hosp Univ Med Oldenburg, Oldenburg, Germany
[2] Roche Pharma AG, Grenzach Wyhlen, Germany
[3] Asklepios Fachkliniken, Munich, Germany
[4] Lungenfachklin Immenhausen, Immenhausen, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P448
引用
收藏
页码：227 / 228
页数：2
相关论文
共 50 条
  • [21] Outcomes to first-line pembrolizumab in patients with non-small cell lung cancer and a PD-L1 tumor proportion score ≥90%.
    Aguilar, Elizabeth Jimenez
    Ricciuti, Biagio
    Gainor, Justin F.
    Nishino, Mizuki
    Adeni, Anika E.
    Subegdjo, Safiya
    Khosrowjerdi, Sara
    Peterson, Rachel
    Digumarthy, Subba
    Liu, Corinne
    Sauter, Jennifer L.
    Rizvi, Hira
    Arbour, Kathryn Cecilia
    Carter, Brett W.
    Heymach, John
    Altan, Mehmet
    Hellmann, Matthew David
    Awad, Mark M.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [22] Real-world first-line treatment with pembrolizumab for non-small cell lung carcinoma with high PD-L1 expression: Updated analysis
    Ikezawa, Yasuyuki
    Morita, Ryo
    Mizugaki, Hidenori
    Tateishi, Kazunari
    Yokoo, Keiki
    Sumi, Toshiyuki
    Kikuchi, Hajime
    Kitamura, Yasuo
    Nakamura, Atsushi
    Kobayashi, Maki
    Aso, Mari
    Kimura, Nozomu
    Yoshiike, Fumiaki
    Megumi, Furuta
    Tanaka, Hisashi
    Sekikawa, Motoki
    Hachiya, Tsutomu
    Nakamura, Keiichi
    Hommura, Fumihiro
    Sukoh, Noriaki
    Ito, Kenichiro
    Kikuchi, Takashi
    Agatsuma, Toshihiko
    Yokouchi, Hiroshi
    CANCER MEDICINE, 2024, 13 (14):
  • [23] Real-World Efficacy of First-Line Pembrolizumab in Patients with Advanced PD-L1 High Non-Small Cell Lung Cancer in Argentina
    Kuzminin, A.
    Minatta, N.
    Bluthgen, M.
    Rizzo, M.
    Naveira, M.
    Wainsztein, V.
    Lupinacci, L.
    Rizzi, M.
    Faura, M.
    Perfetti, A.
    Recondo, G., Jr.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S589 - S590
  • [24] Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer
    Saxena, Puneet
    Singh, Pawan Kumar
    Malik, Prabhat Singh
    Singh, Navneet
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2020, 21 (08)
  • [25] Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial
    Hui, R.
    Garon, E. B.
    Goldman, J. W.
    Leighl, N. B.
    Hellmann, M. D.
    Patnaik, A.
    Gandhi, L.
    Eder, J. P.
    Ahn, M-J
    Horn, L.
    Felip, E.
    Carcereny, E.
    Rangwala, R.
    Lubiniecki, G. M.
    Zhang, J.
    Emancipator, K.
    Roach, C.
    Rizvi, N. A.
    ANNALS OF ONCOLOGY, 2017, 28 (04) : 874 - 881
  • [26] The Role of Immunotherapy in the First-Line Treatment of Elderly Advanced Non-Small Cell Lung Cancer
    Spagnuolo, Alessia
    Gridelli, Cesare
    CANCERS, 2023, 15 (08)
  • [27] Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer
    Puneet Saxena
    Pawan Kumar Singh
    Prabhat Singh Malik
    Navneet Singh
    Current Treatment Options in Oncology, 2020, 21
  • [28] First-line combination immunotherapy for metastatic non-small cell lung cancer
    Chen, Yuh-Min
    JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2020, 83 (05) : 433 - 441
  • [29] Treatment selection and real-world analysis of immunotherapy with or without chemotherapy in PD-L1-high metastatic non-small cell lung cancer
    Smith, Samuel
    Kao, Steven
    Boyer, Michael
    Franco, Michael
    Moore, Melissa
    INTERNAL MEDICINE JOURNAL, 2024, 54 (08) : 1337 - 1343
  • [30] Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression
    Aguilar, E. J.
    Ricciuti, B.
    Gainor, J. F.
    Kehl, K. L.
    Kravets, S.
    Dahlberg, S.
    Nishino, M.
    Sholl, L. M.
    Adeni, A.
    Subegdjo, S.
    Khosrowjerdi, S.
    Peterson, R. M.
    Digumarthy, S.
    Liu, C.
    Sauter, J.
    Rizvi, H.
    Arbour, K. C.
    Carter, B. W.
    Heymach, J. V.
    Altan, M.
    Hellmann, M. D.
    Awad, M. M.
    ANNALS OF ONCOLOGY, 2019, 30 (10) : 1653 - 1659
12345